-
Wednesday 10:30am - 11:30amWEBINAR | Liquid biopsies for tracking molecular resistance in cancer
-
PODCAST | Radio Rare: Professor Sean Grimmond
People with rare cancers have been left behind by traditional standards of care. Professor Sean Grimmond, our director and lead of the Precision Oncology group, spoke to Dr Emily Isham of Rare Cancers Australia on how our work contributing to international genomic knowledge bases is improving diagnosis and therapy for these patients.
-
Caring for the terminally ill in prison
New research highlights the opportunities to improve care for people in prison who are dying from a progressive, life-limiting illness.
-
A health economics perspective on comprehensive genome profiling
Can we use data modelling to show that the extra cost of Comprehensive Genome Profiling is worth it in the long run to the health economy? Health economics expert Professor Maarten IJzerman presents the health economic analysis of implementing comprehensive vs standard of care tumour molecular profiling.
-
Health professionals predict rising challenges for cancer care
Delays in routine cancer care due to COVID19 have health professionals on high alert for a variety of service challenges predicted to arise in coming months.
-
What's gone wrong with managing bowel cancer in Australia?
Using four different approaches, researchers are attacking one of our most prevalent and preventable cancers, with the common goal of saving thousands of lives.
-
New research to benefit patients with hard-to-treat cancer of unknown primary
The effort to improve diagnosis and treatment for patients with Cancer of the Unknown Primary has received a $2.4m from the MRFF, led by Professor Linda Mileshkin at Peter Mac and supported by UMCCR's Professor Sean Grimmond and Dr Richard Tothill.
-
MRFF grant to predict the population health economic impact of new cancer treatments
Professor Maarten IJzerman and collaborators have been awarded more than $2.3m to take a data-driven approach to provide epidemiological estimates of eligible patient populations and quantify the financial impact of new cancer treatments over the next 5 years.
-
Funding to Identify novel therapeutic targets in leukaemia stem cells
Professor Mark Dawson and researchers from the Cancer Therapeutics CRC have been awarded MRFF funding to study and understand the molecular events that underpin the unique properties of leukaemia stem cells and their role in acute myeloid leukaemia, a type of cancer that affects the blood and bone marrow.
-
PODCAST | Radio Rare: Dr Richard Tothill
Dr Richard Tothill from the University of Melbourne Centre for Cancer Research talked to Radio Rare, providing a glimpse into the future of cancer treatments, particularly in cancer of unknown primary (CUP) and Neuroendocrine Tumours (NETs).
-
Research estimates additional 90 cancer deaths and $12m costs in Australia due COVID-19 induced delay
A new model has conservatively estimated that a three-month delay in cancer diagnosis and treatment due to COVID-19 would result in 90 additional deaths and $12 million in additional healthcare costs in Australia over five years.
-
Health economics student network launched in Victoria
A Victorian and Tasmanian chapter of the Professional Society of Health Economics and Outcomes Research (ISPOR) student network has been launched, fostering the development of future leaders in health economic and outcomes research.